In addition, as FGFR2 has been shown to be overexpressed or amplified only in a small percentage of breast cancers [9],[10],[24], it is possible that the association with breast cancer risk could be stronger and more clinically relevant for the small subset of tumors that express high levels of the receptor. This evidence concerns the gene FGFR2 and breast cancer.